Compare SNSC & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SNSC | COCH |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | New Zealand | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 51.0M |
| IPO Year | 2026 | 2021 |
| Metric | SNSC | COCH |
|---|---|---|
| Price | $1.25 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 39.5K | ★ 51.9K |
| Earning Date | 11-19-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | $3.73 |
| Revenue Next Year | N/A | $24.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $1.00 | $0.36 |
| 52 Week High | $3.07 | $1.89 |
| Indicator | SNSC | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 42.92 |
| Support Level | $1.00 | $0.67 |
| Resistance Level | N/A | $0.74 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 62.07 | 11.11 |
SunScout Holding Ltd is a clean-technology company engaged in the design, development, manufacturing, and commercialization of autonomous, solar-powered robotic mowers and related solar energy solutions. Its products are intended as alternatives to petrol-powered and grid-dependent electric lawn mowing equipment. The company's business comprises three lines of products and solutions, which are also its reportable segments: SunScout Products, Solar Power Development Solutions, and Engineering Products and Services. The majority of revenue is derived from the Solar Power Development Solutions segment, which develops and installs solar-energy systems for commercial, industrial, and institutional customers through EPC contracts. Geographically, maximum revenue is derived from New Zealand.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.